Related Experiment Videos
D-1 and D-2 agonists in Parkinson's disease
A N Lieberman1, M Goldstein, G Gopinathan
1New York University School of Medicine, New York.
Summary
Adding dopamine agonists to levodopa significantly improved advanced Parkinson's disease (PD) symptoms and motor fluctuations in most patients. This combination therapy offered sustained benefits for at least two years with reversible side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Advanced Parkinson's disease (PD) patients often exhibit inadequate response to levodopa alone.
- Motor fluctuations, including "wearing off" and "on-off" phenomena, are common challenges in advanced PD management.
- Previous adjustments to levodopa therapy (dosage, schedule, drug holidays) were frequently unsuccessful in managing these symptoms.
Purpose of the Study:
- To evaluate the efficacy and safety of five dopamine agonists (bromocriptine, lergotrile, lisuride, pergolide, mesulergine) in patients with advanced PD.
- To assess the impact of adding dopamine agonists to existing levodopa treatment on motor disability and fluctuations.
- To determine the long-term effectiveness and tolerability of this combination therapy.
Main Methods:
- A study involving 278 patients with advanced Parkinson's disease.
- Dopamine agonists were administered as an adjunct to levodopa therapy for patients with suboptimal responses.
- Patient outcomes, including parkinsonian disability, diurnal fluctuations, and adverse events, were systematically monitored.
Main Results:
- The addition of dopamine agonists led to a reduction in parkinsonian disability in the majority of patients.
- Significant decrease in the severity of diurnal motor fluctuations was observed.
- Improvements were sustained for at least two years in many patients, with manageable and reversible adverse effects (mental changes, dyskinesias, orthostatic hypotension, nausea).
Conclusions:
- Dopamine agonists, when combined with levodopa, represent a valuable therapeutic strategy for managing advanced Parkinson's disease, particularly for patients experiencing motor fluctuations.
- This combination therapy can improve motor control and reduce symptom variability, offering sustained benefits.
- The primary role of dopamine agonists may be in combination with levodopa for early-stage PD to prevent dyskinesias and fluctuations, though they also benefit advanced cases.